Sanofi hired John Reed, the former top scientist at oncology market leader Roche, to head the drugmaker’s group research operations.

Anika Therapeutics Inc. announced results from the company’s CINGAL 16-02 clinical trial, an active-comparator Phase III study being conducted to support U.S. registration.

Anika announced a research collaboration with the Institute of Integrative Biology at the University of Liverpool to develop an injectable mesenchymal stem cell therapy for osteoarthritis.

Pfizer Inc. is abandoning research to find new drugs aimed at treating Alzheimer’s and Parkinson’s disease.

Flexion Therapeutics Inc.’s injectable drug to treat osteoarthritis-related knee pain was approved by the U.S. Food and Drug Administration, sending the drug developer’s shares soaring to a record high in regular trading.

Flexion Therapeutics scrapped an eight-year-old agreement with pharma giant AstraZeneca to develop an end-stage osteoarthritis treatment.

The Korea Ministry of Food and Drug Safety granted marketing approval for Invossa-K Inj., the world’s first cell and gene therapy for degenerative arthritis.

A synthetic version of a medicine traditionally extracted from chili plant relieved knee pain among osteoarthritis patients for up to six months, data showed, bringing Centrexion Therapeutics a step closer to developing a safe and effective analgesic.

Pfizer Inc. and Eli Lilly and Company announced that the U.S. Food and Drug Administration granted Fast Track designation for tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP).

Drugmaker Regeneron Pharmaceuticals Inc said on Monday its experimental drug to treat moderate-to-severe osteoarthritis pain was successful in a late-stage study.